IP Library › Granted Patent US 8,236,763
Granted Patent B2
US 8,236,763 · App. 10/598,736 · Granted Aug 7, 2012

Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,236,763
App. No.
10/598,736
Granted
Aug 7, 2012
Kind
B2
Abstract

The invention relates to the use of antagonists to the CB1 receptor for the preparation of a composition for the treatment of hepatic diseases and preferably to the use of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide.

Claims (1)

1. A method of reducing hepatic fibrosis in a mammal in need thereof which comprises administering a therapeutically effective amount of at least one CB1 receptor antagonist.

Assignments (2)
CHANGE OF NAME Recorded Jun 20, 2012
From: SANOFI-AVENTIS
To: SANOFI
Reel/Frame 028413/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2007
From: LOTERSZTAJN, SOPHIE; MALLAT, ARIANE; GRENARD, PASCALE; JULIEN, BORIS; TRAN VAN NHIEU, JEANNE
To: INSERM; SANOFI-AVENTIS
Reel/Frame 019579/0650 →